Tempus AI, Inc. × Recursion Pharmaceuticals, Inc.
Announced alongside a separate data deal, Tempus agreed to pay Recursion $12 million over two years to license Recursion's TxFM RNA foundation model. [32, 48] The non-exclusive license allows Tempus to use the AI model for its internal R&D, as well as for diagnostic and clinical applications within oncology. [49] This agreement highlights the emerging market for licensing pre-trained AI models between specialized biotech firms. [32]
The asset
A two-year, non-exclusive worldwide license to Recursion's proprietary RNA sequencing foundation model, 'TxFM', for use in the field of oncology.
The record
- Seller status
- Going concern
- Sector
- AI and drug discovery
- Modalities
- ai_model
- Jurisdiction
- US
What it means if you hold data
This deal is a clear example of AI-native biotechs licensing foundational models from each other as distinct digital assets, creating a new revenue stream and accelerating R&D by acquiring specialized capabilities instead of building them from scratch.